Zagociguat

Zagociguat

SCHEMBL21333489

CCC(C)=O.Fc1ccccc1Cc1nc(-c2nc(C(F)(F)F)n[nH]2)cn2ccnc12

nearest known ligand 0.33

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
NPC1 O15118 1/20 0.33
ATM Q13315 1/20 0.33
EPHB4 P54760 8/20 0.32
PDE5A O76074 1/20 0.32
PDE4A P27815 1/20 0.32
PDE1A P54750 1/20 0.32
PDE1B Q01064 1/20 0.32
PDE4B Q07343 1/20 0.32
PDE4C Q08493 1/20 0.32
PDE4D Q08499 1/20 0.32
PDE1C Q14123 1/20 0.32
AR P10275 1/20 0.32
KDR P35968 2/20 0.31
TEK Q02763 2/20 0.31
RXFP1 Q9HBX9 1/20 0.31
ADORA3 P0DMS8 1/20 0.31
TMIGD3 P0DMS9 1/20 0.31
ABL1 P00519 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Zagociguat SCHEMBL21332766 0.93 PDE5A (0.34) ATMEPHB4PDE5APDE4APDE1A
Zagociguat SCHEMBL21333483 0.93 PDE5A (0.35) MEN1KMT2ANPC1ATMEPHB4
Zagociguat SCHEMBL19922804 0.92 AR (0.34) NPC1ATMEPHB4PDE5APDE4A
Zagociguat SCHEMBL21332823 0.92 EPHB4 (0.32) ATMEPHB4PDE5APDE4APDE1A
Zagociguat SCHEMBL21332996 0.91 AR (0.34) NPC1ATMEPHB4PDE5APDE4A
Zagociguat SCHEMBL21332963 0.89 PDE5A (0.33) PDE5APDE4APDE1APDE1BPDE4B
Zagociguat SCHEMBL21332705 0.89 PDE5A (0.33) PDE5APDE4APDE1APDE1BPDE4B
SCHEMBL19922726 0.85 EPHB4 (0.32) EPHB4KDRTEK
SCHEMBL19922775 0.85 AR (0.33) MEN1KMT2ANPC1ATMAR
SCHEMBL26415379 0.84 AR (0.34) NPC1EPHB4AR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3762389-B1 CRYSTALLINE FORMS OF AN SGC STIMULATOR TISENTO THERAPEUTICS INC (US) 2024-02-28 EP disclosed
US-20230095799-A1 CRYSTALLINE FORMS OF AN sGC STIMULATOR TISENTO THERAPEUTICS INC. 2023-03-30 US disclosed
US-20210115050-A1 CRYSTALLINE FORMS OF AN sGC STIMULATOR TISENTO THERAPEUTICS INC. 2021-04-22 US disclosed
EP-3762389-A1 CRYSTALLINE FORMS OF AN SGC STIMULATOR Cyclerion Therapeutics, Inc. (US) 2021-01-13 EP disclosed
WO-2019173551-A1 CRYSTALLINE FORMS OF AN SGC STIMULATOR CYCLERION THERAPEUTICS, INC. (US) 2019-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210115050-A1 CRYSTALLINE FORMS OF AN sGC STIMULATOR GUCY1A2, GUCY1B2, GUCY1A1 MEN1 3771/4885KMT2A 4588/4885NPC1 3624/4885
US-20230095799-A1 CRYSTALLINE FORMS OF AN sGC STIMULATOR GUCY1A2, GUCY1B2, GUCY1A1 MEN1 3771/4885KMT2A 4588/4885NPC1 3624/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.